Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Pharmaceuticals ETF

101.81
+0.74000.73%
Pre-market: 101.780.2489+0.25%07:00 EDT
Volume:81.58K
Turnover:8.34M
Market Cap:1.63B
PE:9.48
High:103.00
Open:102.65
Low:101.78
Close:101.07
52wk High:108.66
52wk Low:69.02
Shares:16.00M
Float Shares:16.00M
Volume Ratio:0.60
T/O Rate:0.51%
Dividend:1.47
Dividend Rate:1.44%
EPS(TTM):10.74
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly and Co Stock (LLY) Moved Up by 3.01% on Sep 14: Drivers Behind the Movement

TradingKey
·
19 hours ago

Dow Jones Top Company Headlines at 11 am ET: Microsoft Sets Limits for AI Models as Altman Details Control Risks | Dell's ...

Dow Jones
·
Yesterday

Eli Lilly Announces R$ 0.2 Per Unit Dividend for 3Q 2026 BDRs

Reuters
·
Yesterday

Sector Update: Healthcare Stocks Rise Premarket Monday

MT Newswires Live
·
Yesterday

BioMarin Appoints Bristol Myers Squibb Research Chief Robert Plenge to Board

Reuters
·
Yesterday

Press Release: BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors

Dow Jones
·
Yesterday

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Yesterday

J&J - Jnj Reports Rybrevant Plus Chemotherapy Extends Pfs2 by 10.8 Months in Nsclc

THOMSON REUTERS
·
Yesterday

Johnson & Johnson’s Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Delivers Longest Reported Median Overall Survival in Egfr Exon 20 Insertion Mutation-Positive Lung Cancer

THOMSON REUTERS
·
Yesterday

J&J - Jnj Reports no New Safety Signals for Rybrevant Plus Chemotherapy in Nsclc Study

THOMSON REUTERS
·
Yesterday

Potential Buyer Emerges for Johnson & Johnson's Orthopedics Unit

Deep News
·
Yesterday

Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell

MT Newswires Live
·
Yesterday

Perspective Therapeutics Partners with Merck to Test [212Pb]PSV359 with Keytruda in FAP-Α-Positive Solid Tumors

Reuters
·
Yesterday

Perspective Therapeutics, - Co Sponsors Study; Merck Provides Pembrolizumab at no Cost

THOMSON REUTERS
·
Yesterday

Johnson & Johnson reports PAPILLON study meets primary endpoint

TIPRANKS
·
Yesterday

Market Chatter: Apollo Global in Talks to Buy J&J Orthopedics Unit for $20 Billion

MT Newswires Live
·
Yesterday

One State's Battle to Stop People from Taking Unapproved Weight-Loss Drugs

Dow Jones
·
Yesterday

Nanobiotix announces updated safety, efficacy data from JNJ-1900 study

TIPRANKS
·
Yesterday

Johnson & Johnson Says Lung Cancer Drug Combination Extends Median Survival to Over 34 Months

MT Newswires Live
·
Yesterday

J&J Shares up 1.2% Premarket After Report Co's Orthopedics Unit Draws Apollo Interest in Potential $20 Bln Deal

THOMSON REUTERS
·
Yesterday